Log In
Print this Print this

AzaSite Xtra (ISV-405)

  Manage Alerts
Collapse Summary General Information
Company Sun Pharmaceutical Industries Ltd.
DescriptionDurasite formulation of azithromycin (2%)
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPreclinical
Standard IndicationBacterial infection
Indication DetailsTreat ocular infections
Regulatory Designation
PartnerSenju Pharmaceutical Co. Ltd.;
VISUfarma B.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today